CSL Limited ADR news reflects developments from a global biopharma company focused on plasma-derived therapies, vaccines and biotechnology medicines. Recurring updates cover CSL Behring, CSL Seqirus and CSL Vifor activities, including hemophilia and immune-deficiency therapies, influenza vaccines, iron-deficiency and nephrology treatments, and hereditary angioedema products.
Company news also includes clinical data and regulatory decisions for products such as HEMGENIX, ANDEMBRY and FILSPARI, manufacturing investments tied to plasma-therapy capacity and advanced production processes, and ADR program administration for the U.S. over-the-counter security.
Seqirus has published real-world evidence demonstrating the superiority of its cell-based quadrivalent influenza vaccine (QIVc) over standard egg-based vaccine (QIVe-SD) in preventing influenza-related hospitalizations during the 2017/18 flu season. The study, published in Vaccine, involved over 3 million subjects and showed QIVc resulted in lower healthcare resource utilization and hospitalizations. This significant data supports the CDC's annual vaccination recommendation and underscores the importance of QIVc, particularly as COVID-19 persists, emphasizing the urgent need for effective influenza prevention.